论文部分内容阅读
目的探讨参苓白术散与化疗联合治疗胃癌患者的临床效果。方法选取2016年3—12月本溪市中心医院收治的80例胃癌患者为研究对象,随机分为观察组和对照组,各40例。对照组患者接受紫杉醇+替吉奥化疗方案治疗,观察组患者则在对照组基础上应用参苓白术散治疗,比较两组患者近期疗效、不良反应发生情况以及生命质量。结果观察组患者近期疗效(50.0%)明显高于对照组的30.0%,且临床受益率为70.0%明显高于对照组的55.0%,差异均有统计学意义(均P<0.05);观察组患者恶心呕吐、疼痛、肝功能损伤发生率均明显低于对照组,差异均有统计学意义(均P<0.05);观察组患者生命质量总改善率为55.0%明显高于对照组的27.5%,差异有统计学意义(P<0.05)。结论参苓白术散联合化疗能改善胃癌患者的生命质量,缓解不良反应,提高近期疗效。
Objective To investigate the clinical effect of Shenling Baizhu Powder combined with chemotherapy in the treatment of patients with gastric cancer. Methods Eighty gastric cancer patients admitted from March to December 2016 in Benxi Central Hospital were enrolled in this study. The patients were randomly divided into observation group and control group, 40 cases in each. Patients in the control group were treated with paclitaxel plus ticagrelor. The patients in the observation group were treated with Shenling Baizhu San on the basis of the control group. The short-term curative effect, adverse reactions and quality of life were compared between the two groups. Results The short-term efficacy (50.0%) in the observation group was significantly higher than that in the control group (30.0%), and the clinical benefit rate was 70.0%, which was significantly higher than that in the control group (55.0%, both P <0.05) The incidence of nausea and vomiting, pain and liver function impairment in patients were significantly lower than those in control group (all P <0.05). The overall quality of life improvement rate in observation group was 55.0%, significantly higher than that in control group (27.5% , The difference was statistically significant (P <0.05). Conclusion Shenling Baizhu combined with chemotherapy can improve the quality of life of patients with gastric cancer, relieve adverse reactions and improve the short-term efficacy.